Lucy Scientific Discovery Inc. (LSDI)
Lucy Scientific Discovery is an early-stage psychotropics contract manufacturing company focused on becoming the premier contract research, development, and manufacturing organization for the emerging psychotropics-based medicines industry.
In August 2021, Health Canada’s Office of Controlled Substances granted us a Controlled Drugs and Substances Dealer’s Licence. The Dealer’s Licence authorizes us to develop and manufacture (through extraction or synthesis) certain pharmaceutical-grade active pharmaceutical ingredients, or APIs, used in controlled substances and their raw material precursors.
Since current Canadian regulations prohibit the commercial sales of APIs and other products we intend to produce, APIs and other products we intend to produce would only be authorized for sale in Canada for clinical testing purposes in an “institution,” for the purpose of determining the hazards and efficacy of the drug, and for laboratory research in an institution by qualified investigators.
As of the date of our prospectus, we have not manufactured any psychedelics-based products or generated any revenues from the sale of such psychedelics-based products.
301-1321 Blanshard Street
Victoria, BC V8W 0B6
|Fiscal Year||July - June|
|Reporting Currency||US Dollars|
|Christopher McElvany||President, Chief Executive Officer, Chair and Director|
|Steven E. Meyer||Chief Operating Officer|
|Assad J. Kazeminy, Ph.D.||Chief Scientific Officer|
|Jerald D. Heise, Ph.D.||Chief Technology Officer|
|Brian Zasitko CPA, CA||Interim Chief Financial Officer|
|Charles B. Nemeroff, M.D., Ph.D.||Director|
Latest SEC Filings
|Mar 4, 2022||S-1/A||General form for registration of securities under the Securities Act of 1933|
|Jan 21, 2022||S-1||General form for registration of securities under the Securities Act of 1933|
|Sep 27, 2021||DRS||Draft Registration Statement|